ArticleHuman vaccines & immunotherapeutics2021
Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 trials have relied on symptomatic subjects for judging the effectiveness of vaccine candidates, whereas asy-mptomatic subjects have been suspected as the main driver of the pandemic. An assumption of the same impact on symptomatic and asymptomatic breakthrough infections is shown to be flawed, resulting in an overestimate of the vaccines' true effectiveness. Recent available data provide the first large-scale unbiased data on asymptomatic versus symptomatic infections postvaccination, providing a unique opportunity to reassess the true infection rates after vaccination. By this, the breakthrough of the BNT162b2 vaccine is seen to be 12% rather than 5% for a corrected overall efficiency (symptomatic + asymptomatic) of 88% with the original virus strain in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.